Anteris Technologies' (ASX:AVR) subsidiary, Anteris Technologies Global Corp. (ATGC), launched the roadshow for its proposed initial public offering of 14.8 million common shares in the US, according to a Tuesday filing with the Australian bourse.
ATGC applied to list its common stock on the Nasdaq Global Market under the ticker symbol "AVR." The unit intends to grant the underwriters a 30-day option to purchase up to an additional 2.2 million shares at the IPO price, less underwriting discounts and commissions, the filing stated.
Following the offering, ATGC intends to list its CHESS Depositary Interests on the Australian Securities Exchange under the same symbol.
Proceeds will be used to fund the ongoing development of Anteris' DurAVR transcatheter heart valve.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。